CK Regeon Inc. has divulged indirubin derivatives acting as CXXC-type zinc finger protein 5 (CXXC5)/DVL interaction inhibitors reported to be useful for the treatment of skin lesions, wounds, neurodegeneration, metabolic disorders and bone disorders.

Vanderbilt University has identified leucine-rich repeat kinase 2 (LRRK2; dardarin) and LRRK2 (G2019S mutant) inhibitors reported to be useful for the treatment of tauopathies, cancer, Crohn’s disease, type 1 diabetes, leprosy, rheumatoid arthritis, traumatic brain injury and Alzheimer’s disease, among others.

Boehringer Ingelheim Pharma GmbH & Co. KG has synthesized NADPH oxidase 4 (NOX4) inhibitors reported to be useful for the treatment of atherosclerosis, cancer, pulmonary hypertension, inflammatory bowel disease, influenza, retinopathy, sepsis and wet macular degeneration (exudative), among others.

Impact Therapeutics (Shanghai) Inc. has disclosed tricyclic derivatives acting as poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.

The U.S. Court of Appeals for the Federal Circuit reined in a district court that invalidated three claims in an Astellas Pharma Inc. patent protecting bladder drug Myrbetriq (mirabegron) based on a issue that was never argued.

Guangdong HEC Pharmaceutical Co. Ltd. has described programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) interaction inhibitors reported to be useful for the treatment of cancer, infections and autoimmune disease.

Scientists at Centre National de la Recherche Scientifique, Ecole Nationale Supérieure de Chimie de Paris, Universitat de Barcelona and Université Paris Sciences et Lettres have divulged metal complexes (particularly Ru[II]) acting as photosensitizers for photodynamic therapy reported to be useful for the treatment of cancer, dermatological disorders and fungal infections.

Japan Tobacco Inc. has identified NLRP3 inflammasome inhibitors reported to be useful for the treatment of arteriosclerosis, gout, inflammatory bowel disease, amyotrophic lateral sclerosis, multiple sclerosis, metabolic dysfunction-associated steatohepatitis (MASH; formerly nonalcoholic steatohepatitis [NASH]), Alzheimer’s disease and Parkinson’s disease.

Insilico Medicine Inc. has synthesized 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).

Suzhou Longbotai Pharmaceutical Co. Ltd. has disclosed benzimidazole derivatives reported to be useful for the treatment of respiratory syncytial virus (RSV) infections.